BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 9092704)

  • 1. Impermeant antitumor sulfonylurea conjugates that inhibit plasma membrane NADH oxidase and growth of HeLa cells in culture. Identification of binding proteins from sera of cancer patients.
    Kim C; MacKellar WC; Cho NM; Byrn SR; Morré DJ
    Biochim Biophys Acta; 1997 Mar; 1324(2):171-81. PubMed ID: 9092704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor sulfonylurea-inhibited NADH oxidase of cultured HeLa cells shed into media.
    Morré DJ; Wilkinson FE; Kim C; Cho N; Lawrence J; Morré DM; McClure D
    Biochim Biophys Acta; 1996 Apr; 1280(2):197-206. PubMed ID: 8639694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes.
    Morré DJ; Wu LY; Morré DM
    Biochim Biophys Acta; 1995 Nov; 1240(1):11-7. PubMed ID: 7495842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N'-(4-chlorophenyl)urea (LY181984) specific to sera from cancer patients.
    Morré DJ; Reust T
    J Bioenerg Biomembr; 1997 Jun; 29(3):281-9. PubMed ID: 9298713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) at an external site.
    Morré DJ
    Biochim Biophys Acta; 1995 Dec; 1240(2):201-8. PubMed ID: 8541291
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of a cell-surface NADH oxidase to the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenylurea) (LY181984) modulated by redox.
    Morré DJ; Wu LY; Morré DM
    Biochim Biophys Acta; 1998 Mar; 1369(2):185-92. PubMed ID: 9518604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and identification of a protein with capsaicin-inhibited NADH oxidase activity from culture media conditioned by growth of HeLa cells.
    Wilkinson F; Kim C; Cho N; Chueh PJ; Leslie S; Moya-Camarena S; Wu LY; Morré DM; Morré DJ
    Arch Biochem Biophys; 1996 Dec; 336(2):275-82. PubMed ID: 8954575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NADH oxidase activity and growth of HeLa cells by the antitumor sulfonylurea, N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984) and response to epidermal growth factor.
    Morré DJ; Wu LY; Morré DM
    Biochim Biophys Acta; 1997 Feb; 1355(2):114-20. PubMed ID: 9042331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A protein disulfide-thiol interchange activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N'-(4-chlorophenyl) urea (LY181984).
    Morré DJ; Jacobs E; Sweeting M; de Cabo R; Morré DM
    Biochim Biophys Acta; 1997 Apr; 1325(1):117-25. PubMed ID: 9106489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sulfonylurea-inhibited NADH oxidase activity of HeLa cell plasma membranes has properties of a protein disulfide-thiol oxidoreductase with protein disulfide-thiol interchange activity.
    Morré DJ; Chueh PJ; Lawler J; Morré DM
    J Bioenerg Biomembr; 1998 Oct; 30(5):477-87. PubMed ID: 9932650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 33.5-kDa heat- and protease-resistant NADH oxidase inhibited by capsaicin from sera of cancer patients.
    Chueh PJ; Morré DJ; Wilkinson FE; Gibson J; Morré DM
    Arch Biochem Biophys; 1997 Jun; 342(1):38-47. PubMed ID: 9185612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A drug-responsive and protease-resistant peripheral NADH oxidase complex from the surface of HeLa S cells.
    del Castillo-Olivares A; Yantiri F; Chueh PJ; Wang S; Sweeting M; Sedlak D; Morré DM; Burgess J; Morré DJ
    Arch Biochem Biophys; 1998 Oct; 358(1):125-40. PubMed ID: 9750173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New cytotoxic benzo(b)thiophenilsulfonamide 1,1-dioxide derivatives inhibit a NADH oxidase located in plasma membranes of tumour cells.
    Alonso MM; Encío I; Martínez-Merino V; Gil M; Migliaccio M
    Br J Cancer; 2001 Nov; 85(9):1400-2. PubMed ID: 11720481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin?
    Morré DJ; Kim C; Paulik M; Morré DM; Faulk WP
    J Bioenerg Biomembr; 1997 Jun; 29(3):269-80. PubMed ID: 9298712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of a tumor-associated NADH oxidase (tNOX) from the HeLa cell surface.
    Yantiri F; Morré DJ
    Arch Biochem Biophys; 2001 Jul; 391(2):149-59. PubMed ID: 11437345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode of action of the anticancer quassinoids--inhibition of the plasma membrane NADH oxidase.
    Morré DJ; Grieco PA; Morré DM
    Life Sci; 1998; 63(7):595-604. PubMed ID: 9718085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The plasma membrane NADH oxidase of HeLa cells has hydroquinone oxidase activity.
    Kishi T; Morré DM; Morré DJ
    Biochim Biophys Acta; 1999 May; 1412(1):66-77. PubMed ID: 10354495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of plasma membrane NADH oxidase activity and growth of HeLa cells by natural and synthetic retinoids.
    Dai S; Morré DJ; Geilen CC; Almond-Roesler B; Orfanos CE; Morré DM
    Mol Cell Biochem; 1997 Jan; 166(1-2):101-9. PubMed ID: 9046026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture.
    Morré DJ; Bridge A; Wu LY; Morré DM
    Biochem Pharmacol; 2000 Oct; 60(7):937-46. PubMed ID: 10974202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients.
    Cho N; Chueh PJ; Kim C; Caldwell S; Morré DM; Morré DJ
    Cancer Immunol Immunother; 2002 May; 51(3):121-9. PubMed ID: 11941450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.